These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 15648082

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV.
    J Clin Oncol; 2005 Oct 01; 23(28):6992-8. PubMed ID: 16192586
    [Abstract] [Full Text] [Related]

  • 23. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
    Suekane S, Noguchi M, Nakashima O, Yamada S, Kojiro M, Matsuoka K.
    Int J Urol; 2007 Aug 01; 14(8):713-8. PubMed ID: 17681061
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
    Berger AP, Deibl M, Strasak A, Bektic J, Pelzer A, Steiner H, Spranger R, Fritsche G, Bartsch G, Horninger W.
    Urology; 2006 Nov 01; 68(5):1067-71. PubMed ID: 17095070
    [Abstract] [Full Text] [Related]

  • 26. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH.
    Urology; 2004 Feb 01; 63(2):316-20. PubMed ID: 14972481
    [Abstract] [Full Text] [Related]

  • 27. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
    van Oort IM, Schout BM, Kiemeney LA, Hulsbergen CA, Witjes JA.
    Eur Urol; 2005 Oct 01; 48(4):572-6. PubMed ID: 16046051
    [Abstract] [Full Text] [Related]

  • 28. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB, Zerbib M, Mejean A, Rouach Y, Debre B, Peyromaure M.
    Can J Urol; 2009 Oct 01; 16(5):4813-9. PubMed ID: 19796456
    [Abstract] [Full Text] [Related]

  • 29. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH, Bangma CH, Roobol MJ.
    Eur Urol; 2008 May 01; 53(5):901-8. PubMed ID: 18262712
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H.
    BJU Int; 2005 Apr 01; 95(6):751-6. PubMed ID: 15794776
    [Abstract] [Full Text] [Related]

  • 32. Prostate biopsy: who, how and when. An update.
    Djavan B, Milani S, Remzi M.
    Can J Urol; 2005 Feb 01; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [Abstract] [Full Text] [Related]

  • 33. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
    Carter HB, Walsh PC, Landis P, Epstein JI.
    J Urol; 2002 Mar 01; 167(3):1231-4. PubMed ID: 11832703
    [Abstract] [Full Text] [Related]

  • 34. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
    Ito K, Kubota Y, Yamamoto T, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H.
    Cancer; 2001 Feb 15; 91(4):744-51. PubMed ID: 11241242
    [Abstract] [Full Text] [Related]

  • 35. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.
    Eur Urol; 2007 Apr 15; 51(4):931-9. PubMed ID: 16935413
    [Abstract] [Full Text] [Related]

  • 36. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA, Kiemeney LA, Laguna MP, van Riemsdijk MM, Barnett GS, Debruyne FM, de la Rosette JJ.
    Urology; 2005 Feb 15; 65(2):300-5. PubMed ID: 15708042
    [Abstract] [Full Text] [Related]

  • 37. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D, Loewen H, Roggenbuck U, Musch M, Klevecka V.
    BJU Int; 2006 May 15; 97(5):985-91. PubMed ID: 16643480
    [Abstract] [Full Text] [Related]

  • 38. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
    Berger AP, Spranger R, Kofler K, Steiner H, Bartsch G, Horninger W.
    Prostate; 2003 Oct 01; 57(2):93-8. PubMed ID: 12949932
    [Abstract] [Full Text] [Related]

  • 39. Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.
    Krygiel JM, Smith DS, Homan SM, Sumner W, Nease RF, Brownson RC, Catalona WJ.
    J Urol; 2005 Jul 01; 174(1):126-30. PubMed ID: 15947596
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.